PDS Biotechnology Corp. Stock
€2.83
Your prediction
PDS Biotechnology Corp. Stock
Pros and Cons of PDS Biotechnology Corp. in the next few years
Pros
Cons
Performance of PDS Biotechnology Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corp. | -0.490% | 3.744% | -10.229% | -44.588% | -38.094% | -77.301% | -43.984% |
| Larimar Therapeutics Inc. | -1.590% | -2.362% | -8.148% | 58.163% | 51.961% | -40.952% | -24.120% |
| Vaxart Inc. | -2.470% | -14.882% | -3.329% | 10.736% | 46.431% | -88.755% | - |
| aTyr Pharma Inc | -2.960% | -0.606% | -1.796% | 8.609% | 27.132% | -81.257% | -50.602% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When evaluating PDS Biotech’s financial situation through its balance sheets, cash flow statements, income statements, and relevant financial ratios, it becomes evident that the company is currently grappling with significant challenges. The company operates without reported revenues, and its mounting losses raise questions regarding its business model and future sustainability. The financial metrics reflect a crucial need for strategic interventions to improve operations and ultimately achieve profitability.
Liquidity Position: One of the most notable strengths is PDS Biotech's liquidity, evident through a cash reserve of approximately $56 million as of December 31, 2023. This amount provides the company with essential runway to fund ongoing operations while navigating through tough financial periods. The reported net working capital of about $45 million further underscores this position, allowing room for operational maneuvering without immediate financial distress.
Market Capitalization: With a market capitalization of approximately $116.6 million, PDS Biotech remains a player in the biotechnology sector. While this figure is not indicative of complete financial health, it does signify a level of investor confidence in the company's potential, reinforcing the notion that the market has not dismissed the company outright, despite its operational challenges.